- 17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps
- INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association's (ADA) 84th Scientific Sessions. The presentation will be delivered by INHALE-3 Study Protocol Chair Dr. Irl B. Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck.
"We are excited for the first read-out of results from the largest post-market clinical trial MannKind has conducted with Afrezza in the last 10 years," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "The results will speak to the common question about Afrezza: ‘How does inhaled insulin fare when compared head-to-head with usual care?' The full 30-week results of INHALE-3 will be available later this year."
Title: |
The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Injections in Adults with Type 1 Diabetes |
Date: | Saturday, June 22, 2024 |
Times: | 8:00-9:30 AM (ET) with topics/presenters to include: |